ArticleCombinatorial chemistry & high throughput screening2026
LINC00888 Promotes Gastric Cancer Growth and Metastasis by Sponging miR-145-5p to Regulate FZD7 Expression.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo investigate the clinical relevance, biological function, and molecular mechanisms of the long non-coding RNA LINC00888 in gastric cancer (GC).
methodsExpression profiles of LINC00888 were analyzed using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Associations with clinical features-including age, sex, tumor stage, recurrence, and survival were examined. Potential downstream targets were predicted using bioinformatics, and experimental validation was performed in GC cell lines via qRT-PCR, Western blot, and luciferase reporter assays. Functional roles were assessed by proliferation and invasion assays.
resultsLINC00888 was upregulated in GC tissues and cell lines and associated with advanced stage, recurrence, and poor prognosis. Knockdown of LINC00888 reduced cell proliferation and invasion in vitro. Bioinformatics and experimental analyses indicated that LINC00888 may act as a competing endogenous RNA for miR-145-5p, potentially influencing Frizzled-7 (FZD7) expression. DISCUSSION: LINC00888 promotes gastric cancer progression by modulating the miR-145- 5p/FZD7 axis and is associated with poor prognosis. It may serve as a prognostic biomarker and potential therapeutic target in GC. Integration of molecular biomarkers like LINC00888 into emerging IoT-based clinical platforms may further enhance personalized cancer management.
conclusionLINC00888 promotes GC progression via the miR-145-5p/FZD7 ceRNA network and may serve as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
41177801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.